Medline — Key Risks
Revenue Is Dangerously Concentrated in a Few Large Customers and Buying Groups
About 69% of Medline's consolidated net sales — roughly $19.7 billion — flows through contracts with just three Group Purchasing Organizations (GPOs) (Vizient, HealthTrust, and Premier), which negotiate prices on behalf of member hospitals. On top of that, the top five U.S. customers alone accounted for $3.2 billion (11.3%) of net sales. Losing even one major GPO relationship or a key customer contract could cause a sharp revenue drop with little warning, since many contracts can be terminated for convenience.
Nearly Two-Thirds of Net Sales Come Through Prime Vendor Agreements That Can Be Cancelled
Prime Vendor agreements — where Medline acts as a hospital's primary supplier — generated $18.0 billion, or 63.4% of net sales in 2025. Many of these agreements include termination-for-convenience clauses, meaning customers can walk away without cause. If Medline loses ground on service quality or pricing, hospitals can switch suppliers relatively easily.
Heavy Debt Load Constrains Flexibility and Eats Into Cash Flow
Medline carries substantial debt under its Senior Secured Credit Facilities and Senior Notes, with variable-rate borrowings that have already driven higher interest expenses in recent years. Restrictive covenants limit the company's ability to pursue acquisitions, pay dividends, or raise new capital. If cash generation weakens — say, from losing a major customer or a tariff shock — the company could struggle to service its debt or refinance on acceptable terms.
A Massive Tax Receivable Agreement Creates a Long-Tail Cash Obligation
As part of its 2021 buyout and recent IPO structure, Medline entered into a Tax Receivable Agreement (TRA) that obligates it to pay 90% of certain tax benefits to pre-IPO owners. As of December 31, 2025, the recorded TRA liability stands at $3.5 billion, with a potential additional $7.5 billion if all remaining Common Units were exchanged at current prices. These payments are due regardless of whether Medline actually realizes the underlying tax savings, and could require the company to take on new debt to fund them.
Tariffs and Global Supply Chain Exposure Could Raise Costs Significantly
Medline sources products from over 40 countries, including 5% of cost of goods sold from China. New U.S. tariffs on goods from China, Mexico, and Southeast Asia — along with retaliatory measures — directly raise the cost of products Medline sells under fixed-price contracts, making it hard to pass increases through to customers quickly. In 2022, a surge in freight and raw material costs had to be largely absorbed rather than passed on.
Regulatory Risk Is Unusually High Given the Medical Product Nature of the Business
Medline's products are regulated by the FDA and equivalent international bodies, and a failure to maintain clearances can result in import alerts, forced product recalls, or production shutdowns. In January 2024, the FDA issued Import Alerts restricting certain plastic syringes from China, directly disrupting Medline's ability to source that product line. Non-compliance can also trigger exclusion from government healthcare programs like Medicare and Medicaid, which would be devastating given how central hospital customers are to the business.
Internal Controls Are Still Being Built Out — A Real Risk for a Newly Public Company
Medline only recently completed its IPO. The company openly states it does not yet have comprehensive documentation of its internal controls and has not tested them under Section 404 of the Sarbanes-Oxley Act. Management acknowledges it cannot rule out a material weakness (a significant gap in financial reporting safeguards). Any such finding, expected to be formally assessed in the 2026 Annual Report, could shake investor confidence and trigger restatements.